Global Antiemetic Drug Market to Grow at a CAGR of 6%, 2017-2021 with GlaxoSmithKline, Johnson & Johnson, Pfizer & Sanofi Dominating - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Antiemetic Drug Market 2017-2021" report to their offering.

The global antiemetic drug market to grow at a CAGR of 6.13% during the period 2017-2021.

This report, Global Antiemetic Drug Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion operating in this market.

The latest trend gaining momentum in the market is inorganic growth strategies. The inorganic growth strategies are expected to contribute the growth of antiemetic drug market. These inorganic growth strategies include global M&A, partnerships, and regional acquisition. Owing to these inorganic growth strategies, the market penetration of vendors is improved, technological advancement due to mutual collaboration in R&D, and improved the product portfolio.

According to the report, one of the major drivers for this market is increased prevalence of cancer. With this ever-increasing population of cancer patients, effective therapies are necessary to save lives and improve their quality of life. Chemotherapy is widely used therapy to help individuals fight cancer. The data estimated that around 3.8-4.2 million cancer patients undergo chemotherapy treatment every year. However, chemotherapy is associated with many side effects. The majority of chemotherapeutic agents cause serious nausea and vomiting with its treatment. This is termed as CINV. The data also reported that around eight out 10 patients undergoing chemotherapy encounter CINV as a debilitating side effect. It is one of the major factors for premature discontinuation of chemotherapy.

Key vendors:

  • GlaxoSmithKline
  • Johnson & Johnson
  • Pfizer
  • Sanofi

Other prominent vendors:

  • Abbott
  • Bristol-Myers Squibb
  • Cipla
  • Eisai
  • Eli Lilly
  • Glenmark
  • Helsinn Healthcare
  • Heron Therapeutics
  • IPCA Laboratories
  • Lupin
  • Merck
  • Novartis
  • RedHill
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: An overview of emesis

Part 06: Market landscape

Part 07: Pipeline landscape

Part 08: Market segmentation by application

Part 09: Market segmentation by drug class

Part 10: Geographical segmentation

Part 11: Decision framework

Part 12: Drivers and challenges

Part 13: Market trends

Part 14: Vendor landscape

Part 15: Key vendor analysis

For more information about this report visit https://www.researchandmarkets.com/research/v7lp42/global_antiemetic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Gastrointestinal Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Gastrointestinal Drugs